Mehrdad naderi (12 risultati)

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New. In English.

HRD. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New.

Paperback. Condizione: New.

HRD. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New. In English.

Condizione: New.

Paperback. Condizione: New.

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Genetic diseases and disorders are common factors in modern pharmacogenomics. The study of emerging factors in epigenomics are significant for effective drug discovery and formulation, as well as for balancing pharmacological and ethical factors in drug development. The goal of drug discovery is to recognize the new molecular formulations impactful in the treatment of genetic diseases. Further exploration of the move from preclinical drug research to the clinical stage may reveal critical transformations to provide effective medicinal products in the market. As precision medicine evolves, genomics-driven drug discovery may also improve patient outcomes while reducing the trial-and-error approach to prescribing medications, assisting with individualized, targeted healthcare. Genomics-Driven Drug Discovery Through Pharmacogenomics explores the integration of genomics into drug discovery and development in the pharmacogenomics field. It offers effective solutions to address challenges of personalized healthcare, ethical dilemmas, and technological considerations involved in drug discovery. This book covers topics such as medical technology, personalized medicine, and drug development, and is a useful resource for medical professionals, healthcare workers, computer engineers, scientists, pharmacologists, academicians, and researchers.…

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Genetic diseases and disorders are common factors in modern pharmacogenomics. The study of emerging factors in epigenomics are significant for effective drug discovery and formulation, as well as for balancing pharmacological and ethical factors in drug development. The goal of drug discovery is to recognize the new molecular formulations impactful in the treatment of genetic diseases. Further exploration of the move from preclinical drug research to the clinical stage may reveal critical transformations to provide effective medicinal products in the market. As precision medicine evolves, genomics-driven drug discovery may also improve patient outcomes while reducing the trial-and-error approach to prescribing medications, assisting with individualized, targeted healthcare. Genomics-Driven Drug Discovery Through Pharmacogenomics explores the integration of genomics into drug discovery and development in the pharmacogenomics field. It offers effective solutions to address challenges of personalized healthcare, ethical dilemmas, and technological considerations involved in drug discovery. This book covers topics such as medical technology, personalized medicine, and drug development, and is a useful resource for medical professionals, healthcare workers, computer engineers, scientists, pharmacologists, academicians, and researchers.…